NCT02236910View on ClinicalTrials.gov

An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Neuroendocrine Carcinoma

Interventions

OTHER

Lu-DOTA-TATE

Trial Locations (1)

N6A 5W9

London Health Sciences Centre, London

All Listed Sponsors

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT02236910 - An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours | Biotech Hunter | Biotech Hunter